×
S&P 500   3,819.23 (-0.06%)
DOW   31,065.77 (+0.38%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,819.23 (-0.06%)
DOW   31,065.77 (+0.38%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,819.23 (-0.06%)
DOW   31,065.77 (+0.38%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,819.23 (-0.06%)
DOW   31,065.77 (+0.38%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
NYSE:GSK

GSK Stock Forecast, Price & News

$43.92
+0.57 (+1.31%)
(As of 06/29/2022 02:28 PM ET)
Add
Compare
Today's Range
$43.42
$43.94
50-Day Range
$41.24
$45.84
52-Week Range
$37.80
$46.97
Volume
237,499 shs
Average Volume
5.37 million shs
Market Capitalization
$111.64 billion
P/E Ratio
15.86
Dividend Yield
3.14%
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock Forecast (MarketRank)

Overall MarketRank

1.65 out of 5 stars

Medical Sector

977th out of 1,433 stocks

Pharmaceutical Preparations Industry

488th out of 685 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
GSK logo

About GSK (NYSE:GSK)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK Stock News Headlines

Brokerages Set GSK plc (NYSE:GSK) Target Price at $1,850.00
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
90,096
Year Founded
2000

Company Calendar

Ex-Dividend for 4/7 Dividend
2/24/2022
Dividend Payable
4/07/2022
Last Earnings
4/27/2022
Ex-Dividend for 7/1 Dividend
5/19/2022
Today
6/29/2022
Dividend Payable
7/01/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$6.03 billion
Pretax Margin
17.83%

Debt

Sales & Book Value

Annual Sales
$46.91 billion
Cash Flow
$2.91 per share
Book Value
$10.90 per share

Miscellaneous

Outstanding Shares
2,541,795,000
Free Float
2,287,616,000
Market Cap
$111.64 billion
Optionable
Optionable
Beta
0.64

Social Links















GSK Frequently Asked Questions

Should I buy or sell GSK stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GSK
or view top-rated stocks.

How has GSK's stock price performed in 2022?

GSK's stock was trading at $44.10 at the beginning of the year. Since then, GSK shares have decreased by 0.4% and is now trading at $43.92.
View the best growth stocks for 2022 here
.

Are investors shorting GSK?

GSK saw a increase in short interest in June. As of June 15th, there was short interest totaling 8,890,000 shares, an increase of 74.7% from the May 31st total of 5,090,000 shares. Based on an average trading volume of 5,650,000 shares, the days-to-cover ratio is presently 1.6 days.
View GSK's Short Interest
.

When is GSK's next earnings date?

GSK is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for GSK
.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) released its earnings results on Wednesday, April, 27th. The pharmaceutical company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.11. The pharmaceutical company had revenue of $13.12 billion for the quarter, compared to analysts' expectations of $11.97 billion. GSK had a trailing twelve-month return on equity of 28.13% and a net margin of 14.03%.
View GSK's earnings history
.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a quarterly dividend on Wednesday, May 4th. Investors of record on Friday, May 20th will be given a dividend of $0.3496 per share on Friday, July 1st. This represents a $1.40 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Thursday, May 19th.
View GSK's dividend history
.

Is GSK a good dividend stock?

GSK(NYSE:GSK) pays an annual dividend of $1.37 per share and currently has a dividend yield of 3.14%. The dividend payout ratio of GSK is 49.46%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 40.77% next year. This indicates that GSK will be able to sustain or increase its dividend.
View GSK's dividend history.

Who are GSK's key executives?

GSK's management team includes the following people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 52, Pay $4.88M)
  • Mr. Iain James Mackay, CFO & Exec. Director (Age 60, Pay $3.63M)
  • Dr. Hal V. Barron F.A.C.C., M.D., Chief Scientific Officer, Pres of R&D and Director (Age 59, Pay $6.16M)
  • Ms. Shobie Ramakrishnan, Chief Digital & Technology Officer
  • Ms. Sarah Elton-Farr, Head of Investor Relations
  • Mr. James Ford, Sr. VP & Group Gen. Counsel of Legal & Compliance
  • Ms. Sally Jackson, Sr. VP of Global Communications & CEO Office
  • Ms. Diana Conrad, Chief People Officer
  • Mr. David Simon Redfern, Chief Strategy Officer (Age 56)
  • Mr. Philip C. Thomson, Pres of Global Affairs

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital International Investors (0.75%), Fisher Asset Management LLC (0.75%), Renaissance Technologies LLC (0.39%), Arrowstreet Capital Limited Partnership (0.38%), Black Creek Investment Management Inc. (0.36%) and JTC Employer Solutions Trustee Ltd (0.35%).
View institutional ownership trends for GSK
.

Which institutional investors are selling GSK stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Black Creek Investment Management Inc., Renaissance Technologies LLC, Northern Trust Corp, The Manufacturers Life Insurance Company , Clark Estates Inc. NY, Group One Trading L.P., Bank of New York Mellon Corp, and Financial Counselors Inc..
View insider buying and selling activity for GSK
or view top insider-selling stocks.

Which institutional investors are buying GSK stock?

GSK stock was acquired by a variety of institutional investors in the last quarter, including JTC Employer Solutions Trustee Ltd, Arrowstreet Capital Limited Partnership, Goldman Sachs Group Inc., Acadian Asset Management LLC, Fisher Asset Management LLC, Nomura Holdings Inc., Aaron Wealth Advisors LLC, and National Bank of Canada FI.
View insider buying and selling activity for GSK
or or view top insider-buying stocks.

How do I buy shares of GSK?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $43.92.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $111.64 billion and generates $46.91 billion in revenue each year. The pharmaceutical company earns $6.03 billion in net income (profit) each year or $2.769990 on an earnings per share basis.

How many employees does GSK have?

GSK employs 90,096 workers across the globe.

When was GSK founded?

GSK was founded in 2000.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for GSK is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at [email protected], or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.